Biomedicines: a revolution... with two main challenges to meet.
Over the past twenty years, the healthcare industry and patients have been experiencing a veritable revolution with the arrival of drugs whose active substance are produced from living organisms.
The development of these biomedicines has opened up new hopes for treatments in many therapeutic areas (oncology, immunology, virology, rare diseases, etc.). Biotherapies can therefore have an impact on the daily lives and health of millions of patients. Although France has many assets in this field, it currently imports 95% of the biomedical products sold in its territory.
Moreover, while the diversity and richness of the French ecosystem in this field is a real strength, it also means that a multitude of players from different spheres must be brought on board in order to converge around common projects and successes.
France BioLead, the catalyst for French biomanufacturing players.
It is as a result of these two observations and under the impetus of the Grand Défi Biomédicaments and the Comité Stratégique de Filière des Industries et Technologies de Santé (CSF-ITS) that the France BioLead Association was created in the summer of 2022 by 15 founding members, players in all biomanufacturing value chains: Alliance Innovation Santé Nouvelle-Aquitaine (ALLIS-NA), Capgemini, CEA, Clean Biologics, Enosis Santé (BioValley France, Eurobiomed, Lyonbiopôle Auvergne-Rhône-Alpes and Medicen Paris Region), France Biotech, Genopole, GTP Bioways, Inserm, Leem, Merck, Polepharma, Sanofi, Servier, Thermo Fisher Scientific.
As the sole contact for the Agence de l'Innovation en Santé, the French government, and other players in the biomanufacturing sector (healthcare manufacturers, third-party producers, equipment manufacturers, etc.), France BioLead is the spokesperson for the innovative biomanufacturing sector at the national and international levels.
France BioLead supports the development of the various technological value chains of a sovereign and innovative French biomanufacturing, throughout the life cycle of biomedicine. Thus, among its objectives, the association has set itself the goal of doubling the share of biomedicines produced on French soil by 2030, to promote our sovereignty in the field of health and develop our competitiveness beyond our borders. At the same time, France BioLead intends to double the number of jobs in the sector by 2030 (objective: 20,000 jobs, compared to 10,000 at present).
